Canopy Growth Corp (CGC) research
Canopy Growth Corp- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $0.88
- As of
Canopy Growth Corp (CGC): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-07.
As of . Source: SEC EDGAR filings for CGC. Method and limitations.
Share the CGC intelligence card
See the full CGC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CGC on one page. Preview it with sample data, then open it live with a free account.
Preview the CGC dossierActive signals for CGC
- mediumEARNINGS_BEAT
Q1-2027: Beat consensus by 74.0%, EPS $-0.03 vs $-0.1156 estimate
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in CGC
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 59% of CGC (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 98% of CGC (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 96% of CGC (2026Q2)
FREE, NO ACCOUNT
Every signal on CGC, as it fires
You are seeing 5 of 11 signals recorded on CGC since 2026-05-16.
The five above landed across 2 days. The other 6 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CGC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 138035704 · 2026Q2 | $471K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 138035704 · 2026Q2 | $267K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 138035704 · 2026Q2 | $51K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 138035704 · 2026Q2 | $29K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 138035704 · 2026Q2 | $27K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CGC
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CGC mentioned in Kresmion daily briefs
CGC against its peers
CGC's operating margin of -56.8% ranks in the 14th percentile of 17 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | CGC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 285M CAD | n/a | n/a | 0 |
| Gross margin | 24.5% | 48.4% | 4 | 12 |
| Operating margin | -56.8% | -4.3% | 14 | 17 |
| Net margin | -92.4% | -18.7% | 14 | 17 |
| Return on equity | -37.7% | -19.3% | 23 | 14 |
Peers (19): NIKA, VRNO, KMDA, TKNO, EOLS, VREOF, TLRY, AQST, ELTP, AKBA, CRLBF, DERM, CRDL, TSNDF, ADCT, HROW, GRUSF, AAWH, CPIX. Left out: LFCR (no annual filing), EVO (period gap), PHBI (period gap), BORAY (no annual filing), ASRT (no annual filing), OGI (period gap). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (CGC: 10-K), reported in CAD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CGC signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CGCand get the insider, 13F, options, and confluence read in one view.